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Ferroportin is the sole cellular efflux channel for iron and is regulated by the iron regulatory hormone hepcidin, which
binds ferroportin and induces its internalization and degradation. New studies of ferroportin knockout mice define a key
role for this transporter in physiological iron balance.Iron, an essential nutrient, is used in pro- r
teins that store and transport oxygen s
fand catalyze redox reactions. In verte-
brates, most iron in the body is destined a
sfor hemoglobin. When iron absorption
from the diet is not sufficient to compen- s
isate for iron losses, hemoglobin pro-
duction decreases, resulting in anemia. c
INot only is iron deficiency deleterious,
but iron excess is also. Uncomplexed m
firon catalyzes the production of reactive
oxygen species which cause cellular in-
pjury and cell death. In hereditary hemo-
chromatoses (Pietrangelo, 2004), unre- c
astrained iron absorption from the diet
leads to the deposition of excess iron in c
fthe liver and other organs, with conse-
quent organ damage and functional fail- p
rure. In this issue of Cell Metabolism,
Andrews and colleagues use genetic f
bmeans to demonstrate the unique and
nonredundant function of the cellular i
ciron exporter ferroportin in maintaining
extracellular iron homeostasis (Donovan n
Tet al., 2005).
Cellular iron homeostasis (Hentze et c
tal., 2004) assures adequate iron supply
for the varying metabolic needs of indi- w
mvidual cells, as long as extracellular iron
concentrations remain in the normal i
orange. Iron circulates in plasma or extra-
cellular fluid complexed with transferrin. a
tCells take up iron-transferrin by transfer-CELL METABOLISM : MARCH 2005in receptor-mediated endocytosis and
ttore iron predominantly in cytoplasmic
erritin. Two iron regulatory proteins (IRP1 f
ind IRP2) function as cytoplasmic iron
ensors. When cellular iron is low, IRPs v
etabilize transferrin receptor mRNA, thus
ncreasing the number of transferrin re- s
ieptors for iron uptake. Iron-deficient
RPs also inhibit the translation of ferritin v
DRNA, allowing the net release of iron
rom ferritin. i
eOrganismal iron homeostasis has ap-
arently evolved to maintain a stable con- i
sentration of iron-transferrin in plasma
nd extracellular fluid. This requires the (
2oordinated control of three major iron
lows into the plasma transferrin com- o
tartment: iron absorption from the envi-
onment (maternal plasma iron in the u
aetus and intestinal dietary iron after
irth), movement of iron out of storage d
(n the liver, and recycling of the iron
ontent of senescent cells (predomi- 2
cantly red blood cells) by macrophages.
o maintain stable extracellular iron con- i
aentrations, the inflow of iron into plasma
ransferrin must balance the outflow, t
phich is dominated by the iron require-
ents of red cell hemoglobin production
cn the bone marrow. Additional smaller
utflows supply the needs of other cells, f
ind the rest enters into storage in hepa-
ocytes. lInfluences other than the concentra-
ion of iron-transferrin also regulate iron
lows. Anemia and hypoxia stimulate
ron absorption and recycling, thus pro-
iding more iron for compensatory
rythropoiesis. Moreover, both iron ab-
orption and recycling are inhibited dur-
ng infections, presumably to deprive in-
ading pathogens of extracellular iron.
espite the potential for great complex-
ty, the regulatory system that has
merged from recent studies is surpris-
ngly simple and elegant (Figure 1). The
ingle iron regulatory hormone, hepcidin
Nicolas et al., 2001, 2002; Roetto et al.,
003; Ganz, 2004), controls iron flows
ut of the cells and into the plasma
ransferrin compartment by binding to a
nique cellular iron exporter, ferroportin,
nd inducing its endocytosis and degra-
ation (Nemeth et al., 2004). Ferroportin
McKie et al., 2000; Donovan et al.,
000; Abboud and Haile, 2000), also
alled Slc40a1, MTP1, or Ireg1, is found
n all the tissues where major iron flows
re regulated, including duodenal en-
erocytes, placental trophoblast, macro-
hages, and hepatocytes.
The work of Donovan et al. has signifi-
antly advanced our understanding of
erroportin’s function. Their earlier studies
n zebrafish indicated that the complete
oss of ferroportin expression is embry-155
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Figure 1. Homeostatic regulation of plasma iron e
Ferroportin functions as a hepcidin-regulated valve that controls the efflux of recycled, dietary, and stored r
iron into plasma transferrin. In turn, hepcidin levels are controlled by an as yet undefined plasma iron sensor.
lOxygen and inflammatory cytokines also regulate hepcidin.
g
c
tonic lethal, unless the embryos are res- i
mcued by iron injections (Donovan et al.,
2000). The surviving zebrafish had se- i
vere iron deficiency anemia and were r
pnot able to absorb iron from their diet.
In the current study, total deficiency of
ferroportin in mammals is also embry- o
onic lethal, almost certainly because the c
developing embryo cannot import iron c
across the maternal-fetal interface (ex- e
traembryonic visceral endoderm, pla- t
centa). If this early defect is selectively o
circumvented by conditionally deleting c
tferroportin in all tissues except the ma-
ternal-fetal interface, the embryo sur- h
vives to birth but the newborn mouse l
rapidly develops severe iron deficiency i
as it begins to depend on intestinal ab- l
sorption of iron. The mice also display t
defects in the release of iron from he- s
patic storage and in the recovery of iron r
from recycled red cells. As indicated by t
abundant trapped iron in intestinal en- h
terocytes, macrophages, and hepato- o
cytes, all these cells are unable to export
cytoplasmic iron to plasma in the ab- c
sence of ferroportin. a
tThe importance of ferroportin for in-
testinal iron absorption was specifically p
addressed by an intestine-specific abla- m
tion of ferroportin expression. Like the i
smice with total postnatal ablation of fer-
roportin, these mice also developed se- d
vere systemic iron deficiency despite t156lron-loaded enterocytes. Here, however,
acrophages and hepatocytes lacked h
ron, since these cell types still had fer- m
oportin, and exported iron as is appro-
riate in systemic iron deficiency. T
Most discussions of diseases of iron D
verload make the point that physiologi-
al excretion of iron is very limited and D
annot be increased. However, Donovan U
t al. (2005) propose that intestinal epi- L
helium can take up significant amounts
f iron from plasma by transferrin re-
Septor-mediated endocytosis through
he basolateral membrane. If circulating A
epcidin concentrations are high, baso- C
ateral ferroportin is degraded and the
D
ron trapped. At the end of their 1–2 day P
ife span, the iron-loaded intestinal epi- B
helial cells would be shed into the fecal 7
tream. It is therefore conceivable (but
D
emains to be shown and quantified) G
hat iron excretion in stool could be (
omeostatically increased during iron
Gverload.
2
This important and definitive study
Honfirms that the iron-exporting tissues
dnd cells have no significant alternative
o the ferroportin iron efflux pathway and M
rovides further support for the funda- W
tental role of the hepcidin-ferroportin
2nteraction in systemic iron homeosta-
is. This interaction is also the key to un- N
erstanding the pathogenesis of heredi- M
Kary hemochromatosis. The excessiventestinal iron absorption characteristic
f this group of diseases results from in-
ppropriately high ferroportin activity
ither because of hepcidin deficiency or,
ess commonly, because of the insensi-
ivity of mutated ferroportin to hepcidin.
t the other end of the spectrum of iron
isorders, anemia of inflammation de-
elops when the cytokine-induced hep-
idin internalizes and degrades ferropor-
in on iron-exporting cells, most notably
acrophages. Recycled iron is trapped,
ecreasing the plasma concentration of
ron and limiting hemoglobin production
n developing erythrocytes in the bone
arrow.
What next? Although we have learned
uch about the role of hepcidin and fer-
oportin in organismal iron homeostasis,
e know very little about how and where
xtracellular iron is sensed and how it
egulates hepcidin production and re-
ease. With the exception of the hepcidin
ene itself, the various mutations that
ause hepcidin deficiency involve pro-
eins of unknown function. The mother
ode of iron regulation is far from ex-
austed, and rich iron biology still re-
ains to be explored.
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